ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies

ARDSLEY, N.Y., Sept. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ARMGO Pharma, Inc., a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today that the U.S. Food and Drug Admi... Biopharmaceuticals, FDA ARMGO Pharma, Rycals, Duchenne Muscular Dystrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news